

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 1167)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL DATA OF KRAS G12C INHIBITOR JAB-21822 AT 2022 ASCO ANNUAL MEETING

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

Reference is made to the Company’s voluntary announcement dated May 27, 2022. The board of directors of the Company (the “**Board**”) is pleased to announce that the Phase I clinical data of KRAS G12C inhibitor JAB-21822 has been published at the 2022 annual meeting of American Society of Clinical Oncology (ASCO) (“**2022 ASCO Annual Meeting**”). The e-poster presentation materials has been available at 8:00 a.m. (Central Time)/9:00 p.m. (Beijing Time) on June 5, 2022 at www.asco.org.

Conclusion of the research results are set out below:

As of April 1, 2022, the Phase I clinical data of non-small cell lung cancer patients with KRAS G12C mutation shows that the overall response rate (ORR) is 56.3% (18/32) and the disease control rate (DCR) is 90.6% (29/32). In 400mg QD and 800mg QD cohorts, the ORR is 66.7% (8/12) and the DCR is 100% (12/12).

JAB-21822 was well tolerated with no dose limited toxicity (DLTs) in the dose escalation phase. The study of the clinical trial is still ongoing and remains open to enrollment.

About JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by the Company. The Company has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated non-small cell lung cancer in the front-line setting; combination therapy with SHP2 inhibitor, anti-PD-1 monoclonal antibody and Cetuximab.

About the Company

The Company is committed to providing more products and solutions to people's health. Our mission is to provide compelling innovations for creating a pipeline of life-changing medicines. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. The Company's R&D centers are located in Beijing and Shanghai of China, and Boston of the United States, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, KRAS G12C Inhibitor JAB-21822 and combination therapies of JAB-21822 successfully. Please visit www.jacobiopharma.com for more information.

On behalf of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, June 6, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Daqing CAI as independent non-executive Directors.